Watch for the New Osteoporosis Med, Romosozumab (Evenity)
September 2019
You'll see some postmenopausal women admitted on the new osteoporosis med romosozumab (Evenity, ee-VEN-ih-tee).
Romosozumab is an injectable monoclonal antibody that blocks sclerostin, a protein involved in bone metabolism. This leads to increased bone growth AND decreased bone breakdown.
Other osteoporosis meds do one or the other.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote